Zydus Lifesciences rises 5% on signing agreement with CVS Caremark; Details
CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...
Daily5d
SGLT2 Inhibitors Linked to Higher Risk of PAD Surgeries Compared to DPP-4 Inhibitors in Veterans with Diabetes: Study
Efficacy and Safety of Paracetamol, Phenylephrine and Chlorpheniramine maleate FDC in Common Cold - ...
Endocrinology Advisor12d
Empagliflozin Not Tied to Risk for New Nonproliferative Diabetic Retinopathy
Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with ...
Endocrinology Advisor16d
SGLT2 Inhibitors vs DPP4 Inhibitors Linked to Lower CVD Risks in T2D
SGLT2 inhibitors vs DPP4 inhibitors were associated with lower total cardiovascular disease risks among patients with type 2 ...
rheumatologyadvisor22d
SGLT2 Inhibitors Provide Cardiorenal Benefits for Patients With SLE and Type 2 Diabetes
Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide significant renal benefits and similar safety outcomes compared with dipeptidyl peptidase 4 (DPP4) inhibitors among patients with systemic ...
Medscape23d
GLP-1s May Cut Risk for Late-Onset Epilepsy
The investigators looked at late-onset seizures and epilepsy (defined as diagnosed after age 55 years) in three classes of glucose-lowering drugs: GLP-1 RAs, dipeptidyl peptidase 4 (DPP-4 ...
ahajournals.org26d
Long‐Term Statin Use Is Associated With Reduced Rates of Adverse Events in Patients With Newly Diagnosed Atrial Fibrillation
The effectiveness of statin use in preventing adverse cardiovascular events in individuals with atrial fibrillation (AF) has remained uncertain. This study aimed to assess whether statin use could ...
Medscape29d
Do GLP-1s Lower VTE Risk in People With Type 2 Diabetes?
among individuals with type 2 diabetes compared with dipeptidyl peptidase 4 (DPP-4) inhibitors, a recent analysis indicated. Overall, GLP-1 agonist use was associated with a 20% reduction in VTE ...